ERYTECH Provides Business Update and Reports Cash Balance at End of Q1 2020

TRYbeCA-1 Phase 3 Trial:

  • More than 75% of the planned~500 patients enrolled
  • Fast-Drack designation granted by U.S. FDA
  • Trial to continue as planned after third independent safety review
  • Interim superiority analysis expected around year-end and final analysis in 2H of 2021

Cash position of € 58.6 million ($64.6 million) at the end of the first quarter 2020

ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update

Menu